These new findings are a milestone for Kleresca® as they strongly support our current range of products including FLE for acne, rosacea and skin rejuvenation and provide strong hints towards new therapeutic areas for Kleresca®
Kleresca® General Manager Mr. Mikkel Schoedt
Kleresca® FLE technology strengthens the Laser Clinics Australia portfolio and will contribute to the continued growth of our business by giving us a competitive lead
Anthea Muir, CEO of Laser Clinics Australia
We are excited to have secured the MDSAP certification as it gears the company for further expansion into key markets. It is essential to have the basics in place and take the right steps at the right time. So during 2019, we will focus on investigating our operational options for entering the US market
General Manager Mikkel Schoedt
This research project focusing on FLE in dermatology opens up for whole new perspectives within immunology and we are excited to be part of it.
Prof. Dr. Søren Skov, University of Copenhagen
sk:n offer a wide range of dermatology and aesthetic treatments across our growing network of clinics. The partnership with Kleresca® further enhances our treatment portfolio with a new and innovative treatment we’re confident our clients are going to love.
Lisa Mason-Poyner, Director of Medical Services at sk:n clinics
This is a great treatment to add to the Kleresca® product portfolio and it offers us potential in all the markets we serve. The rosacea treatment will bolster our profile in therapeutic aesthetics and further define our footprint in the market
Mr. Mikkel Schoedt, General Manager of Kleresca®
The CE mark approval is a significant accomplishment for Kleresca® as it is based on a quality management system that we have tailored to our business from scratch securing a high degree of flexibility and agility in our day to day work while still being compliant. This enables us to continue to grow in a rapidly changing market”
Mr. Mikkel Schoedt, General Manager of Kleresca®